Reporting the Granting of Stock Options
(Listed on the TSX Venture Exchange – Symbol ‘APL')
CALGARY, AB / ACCESSWIRE / September 27, 2024 / Appulse Corporation ("Appulse" or the "Corporation") (TSXV:APL) today reported the granting of an aggregate of 775,000 options to purchase common shares of the Corporation to Directors of the Corporation at a price of 20 cents per share. The options are exercisable over a five-year term, expiring September 26, 2029.
About Appulse
On November 1, 2023, the Corporation divested of its primary operating subsidiary, Centrifuges Unlimited Inc. and subsequently completed the payment of a dividend (15 cents per share) and a further capital reduction distribution (13.5 cents per share), to shareholders during 2024. The Corporation continues to identify and analyze new investment opportunities with the goal of enhancing shareholder value.
Further information on Appulse can be obtained on the SEDAR+ profile of Appulse at www.sedarplus.ca.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Doug Baird, President, Telephone: (403) 807-0717 Email: dabaird@shaw.ca or
Dennis Schmidt, CFO, Telephone: (403) 466-1858 Email: dennis@balisardo.ca
SOURCE: Appulse Corporation
View the original press release on accesswire.com
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks